NewAmsterdam extends obicetrapib's LDL story into an Alzheimer's biomarker signal
A poster at AAIC 2026 builds on a prespecified BROADWAY biomarker analysis that already showed a p-tau217 reduction at 12 months, positioning the LDL-lowering drug for a disease it was never designed to treat.
Executive Summary
- NewAmsterdam Pharma is bringing biomarker findings from its completed cardiovascular trial to a major Alzheimer's research conference, extending the drug's evidence base beyond the disease it was designed to treat.
- A prespecified analysis of trial participants found a reduction in a blood marker of Alzheimer's pathology after a year of treatment, with the largest effect concentrated in a small subgroup of genetically high-risk carriers.
- The analysis was not adjusted for baseline imbalances between treatment groups, and the subgroup driving the strongest signal was small enough that its result should be read as hypothesis-generating rather than confirmatory.
- Obicetrapib remains the only Phase 3 CETP inhibitor active in this cardiovascular population, so any new biological signal from its dataset has no direct in-class comparator to weigh it against.
The presentation
NewAmsterdam Pharma announced on July 1, 2026 that it will present four analyses from its BROADWAY trial at AAIC 2026 in London, running July 12 to 15. The July 15 poster, titled "CETP Inhibition for Alzheimer's Prevention: Obicetrapib's Multi-Pathway Effects on Lipid Mediated Pathophysiology," is one of three posters and one oral presentation drawn from the same trial data. BROADWAY (NCT05142722) is a completed, randomized, placebo-controlled Phase 3 study of 2,530 patients with heterozygous familial hypercholesterolemia and/or established atherosclerotic cardiovascular disease, run on top of maximally tolerated lipid-lowering therapy. Its primary endpoint measured the percent change in LDL-C from baseline to Day 84, not any Alzheimer's-related outcome. NewAmsterdam+1NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association ...Jul 1, 2026Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesNCT05142722
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The design: a prespecified biomarker substudy
The Alzheimer's analysis drew on 1,535 BROADWAY participants whose ApoE genotype could be determined, including 367 ApoE4 carriers (ApoE3/E4 or ApoE4/E4). It measured plasma p-tau217, a blood biomarker associated with Alzheimer's pathology, over 12 months of obicetrapib versus placebo. NewAmsterdam disclosed that because the analysis was a subset of a trial designed to evaluate LDL-C reduction, it was not adjusted for baseline differences between the treatment and placebo populations, though the company said statistical analyses were still applied. NewAmsterdamNewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association ...Jul 1, 2026
The result
The analysis found a statistically significant reduction in p-tau217 at 12 months across the full analysis set and in ApoE4 carriers, with a 20.5% reduction reported in the ApoE4/E4 subgroup of 29 patients. That subgroup finding, presented alongside the broader ApoE4-carrier result, is the sharper of the two: a homozygous-risk population moving by a fifth on a pathology marker is a bigger number than the full-cohort signal, though it rests on a subgroup roughly a tenth the size of the ApoE4-carrier population it sits inside. A companion poster at the same conference, "ApoE4-Dependent Dose Response to CETP Inhibition," frames this as informing enrichment strategies for a future Alzheimer's prevention trial rather than as a completed readout. NewAmsterdamNewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association ...Jul 1, 2026
Trial and program context
BROADWAY completed in September 2024 after four primary-completion-date revisions and three enrollment adjustments during its 2021-2024 run, ending at its registered target of 2,530 patients. The company's Phase 2 and Phase 3 obicetrapib programs, including BROOKLYN, BROADWAY, TANDEM, and the ongoing PREVAIL cardiovascular outcomes trial, have consistently shown LDL-lowering with a side-effect profile the company describes as similar to placebo. Menarini's European marketing authorization application for obicetrapib, built on BROOKLYN and BROADWAY data, was validated by the European Medicines Agency in September 2025, underscoring that the drug's primary regulatory path remains cardiovascular, not neurological. NCT05142722+1Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesNCT05142722NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association ...Jul 1, 2026
Where it sits competitively
Obicetrapib is the only CETP inhibitor in Phase 3 testing within the ASCVD/HeFH population. No other CETP inhibitor or Alzheimer's-focused competitor occupies this specific biomarker niche, so the AAIC data have no direct in-class result to be measured against; the comparison that exists is internal, across obicetrapib's own trial population, not external to a rival program. NCT05142722Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesNCT05142722
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.